Cassoux Nathalie, Lumbroso Livia, Levy-Gabriel Christine, Aerts Isabelle, Doz François, Desjardins Laurence
Ocular Oncology, Institut Curie, Paris, France.
Paris Science Letter University, School of Medicine, Université René Descartes, Paris, France.
Asia Pac J Ophthalmol (Phila). 2017 May-Jun;6(3):290-295. doi: 10.22608/APO.201778.
Retinoblastoma is a rare cancer in children, where in less than a century of dire mortality there has been a cure in industrialized countries. Unfortunately, mortality remains high in emerging countries. The evolution of treatment makes it possible to go further by preserving the eyeball but this must not be done at the cost of the reappearance of metastases. Herein we outline the evolution of treatment from the beginning of the 20th century until the last recent evolutions, trying to imagine what could be the future treatments. In this pathology, the ophthalmologist is a doctor who must cure his patient and enucleation is considered a failure. This situation should not lead to shizophrenic situations where to keep an eye one would take risks with the life of the child. New international classifications, international prospective multicentric studies, and the search for blood biomarkers that can predict the risk of micrometastases could allow for better stratification of patients.
视网膜母细胞瘤是一种儿童罕见癌症,在不到一个世纪的高死亡率情况下,工业化国家已实现治愈。不幸的是,新兴国家的死亡率仍然很高。治疗的进展使得在保留眼球方面能够更进一步,但绝不能以转移复发为代价。在此,我们概述了从20世纪初到最近的最新进展的治疗演变,试图设想未来的治疗方法可能是什么。在这种疾病中,眼科医生的职责是治愈患者,眼球摘除被视为治疗失败。这种情况不应导致精神分裂的局面,即保留眼球却要拿孩子的生命冒险。新的国际分类、国际前瞻性多中心研究以及寻找能够预测微转移风险的血液生物标志物,可能会使患者得到更好的分层。